Logo

Galapagos Genomics Identifies Several Drug Targets

Jun 07, 2004

NEW YORK, June 7 (GenomeWeb News) - Galapagos Genomics said today that it has identified, validated, and filed patent applications for several novel drug targets in Alzheimer's disease, osteoporosis, osteoarthritis, rheumatoid arthritis, and asthma.

 

Galapagos identified the targets using its FlexSelect adenoviral-based over-expression and SilenceSelect siRNA gene knockdown technologies.

 

"We are very pleased to see that our target discovery engine in combination with our disease biology expertise has delivered an exiting set of proprietary targets that are ready to be taken into small molecule screening," Onno van de Stolpe, CEO of Galapagos, said in a statement.

 

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.